Peptides having more than 20 amino acids and gastrins and somatostatins and melanotropins and derivatives thereof (C07K14)

C07K14/005 - Epstein-barr virus(5)
C07K14/01 - Dna viruses(12)
C07K14/025 - Shigella (g)(15)
C07K14/04 - Varicella-zoster virus(2)
C07K14/045 - Toxoplasma(2)
C07K14/05 - Epstein-barr virus(2)
C07K14/075 - Fibrinogen(3)
C07K14/08 - Rna viruses(8)
C07K14/13 - Canine distemper virus(3)
C07K14/135 - (3)
C07K14/145 - (5)
C07K14/155 - (5)
C07K14/16 - Hiv-1(23)
C07K14/175 - (2)
C07K14/185 - (2)
C07K14/19 - Rubella virus(47)
C07K14/195 - (47)
C07K14/205 - (2)
C07K14/21 - From pseudomonadaceae (f)(13)
C07K14/215 - (5)
C07K14/23 - From brucella (g)(6)
C07K14/235 - (6)
C07K14/245 - (12)
C07K14/25 - Shigella (g)(6)
C07K14/255 - (5)
C07K14/26 - Klebsiella (g)(1)
C07K14/265 - (1)
C07K14/28 - From vibrionaceae (f)(4)
C07K14/285 - (1)
C07K14/29 - From richettsiales (o)(3)
C07K14/295 - (3)
C07K14/31 - From staphylococcus (g)(29)
C07K14/315 - (17)
C07K14/32 - From bacillus (g)(12)
C07K14/325 - (10)
C07K14/33 - From clostridium (g)(11)
C07K14/335 - (1)
C07K14/34 - From corynebacterium (g)(3)
C07K14/345 - (1)
C07K14/35 - From mycobacteriaceae (f)(10)
C07K14/355 - (1)
C07K14/365 - (1)
C07K14/37 - From fungi(12)
C07K14/375 - (3)
C07K14/38 - From aspergillus(4)
C07K14/385 - (2)
C07K14/39 - From yeasts(6)
C07K14/395 - (3)
C07K14/40 - From candida(3)
C07K14/405 - (1)
C07K14/41 - From lichens(55)
C07K14/415 - (54)
C07K14/425 - (2)
C07K14/43 - Thaumatin(116)
C07K14/435 - (116)
C07K14/44 - From protozoa(6)
C07K14/445 - (3)
C07K14/45 - Toxoplasma(1)
C07K14/455 - (1)
C07K14/46 - From vertebrates(17)
C07K14/465 - (2)
C07K14/47 - From mammals(170)
C07K14/475 - (34)
C07K14/48 - Nerve growth factor (ngf)(8)
C07K14/485 - (6)
C07K14/495 - (4)
C07K14/505 - (25)
C07K14/515 - (14)
C07K14/525 - (14)
C07K14/535 - (15)
C07K14/54 - Interleukins (il)(35)
C07K14/545 - (5)
C07K14/55 - Il-2(22)
C07K14/555 - (11)
C07K14/56 - Ifn-alpha(21)
C07K14/565 - (8)
C07K14/57 - Ifn-gamma(37)
C07K14/575 - (35)
C07K14/585 - (17)
C07K14/595 - (4)
C07K14/605 - (41)
C07K14/62 - Insulins(70)
C07K14/625 - (1)
C07K14/63 - otilins(11)
C07K14/635 - (9)
C07K14/655 - (36)
C07K14/66 - Thymopoietins(1)
C07K14/665 - (1)
C07K14/685 - (1)
C07K14/69 - Beta-melanotropin(10)
C07K14/695 - (10)
C07K14/70 - Enkephalins(80)
C07K14/705 - (74)
C07K14/715 - (19)
C07K14/72 - For hormones(6)
C07K14/725 - (3)
C07K14/73 - Cd4(1)
C07K14/735 - (1)
C07K14/745 - (29)
C07K14/75 - Fibrinogen(18)
C07K14/755 - (12)
C07K14/76 - Albumins(18)
C07K14/765 - (12)
C07K14/77 - Ovalbumin(14)
C07K14/775 - (13)
C07K14/785 - (2)
C07K14/795 - (2)
C07K14/80 - Cytochromes(22)
C07K14/805 - (13)
C07K14/81 - Protease inhibitors(17)
C07K14/815 - (1)

Antigen-binding molecule, able to multiplely contact with plurality of antigenic molecules // 2642318
FIELD: biotechnology.SUBSTANCE: molecule containing a human antigen-binding domain and a FcRn-binding domain with antigen-binding activity different in two different conditions of calcium concentration and lower in conditions of low calcium concentrations compared to the conditions of high calcium concentration, where the low calcium concentration represents the concentration of ionized calcium of 0.1 to 30 mcm, and the high calcium concentration is ionized calcium concentration of 100 mcm to 10 mm, where the specified antibody contains at least four amino acids selected from the group consisting of amino acids at positions 30, 31, 32, 50 and 92, in accordance with the numbering along the Kabat light chain, with chelant activity against metal. Also, a pharmaceutical composition comprising the antibody is described. The invention can be used to accelerate the capture of the antigen by antigen-binding molecules into cells, increase the number of times of antigen binding by one molecule, accelerate the reduction of antigen concentration in plasma and increase the retention of an antigen-binding molecules in the plasma, as well as antigen-binding molecules.EFFECT: decreased antigen concentration in plasma.5 cl, 56 dwg, 28 tbl, 25 ex

Fusion serpine polypeptides and methods for their application // 2642310
FIELD: biotechnology.SUBSTANCE: invention relates to the field of fusion proteins for serine proteases inhibition, and can be used in medicine. Fusion proteins having at least one human alpha-1 antitrypsin (AAT) polypeptide operably linked to an immunoglobulin Fc polypeptide having an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:6 are obtained.EFFECT: invention allows to obtain a fusion polypeptide capable of effectively inhibiting the activity of serine proteases and thereby alleviating the symptoms of diseases or disorders associated with overexpression or serine protease activity in a subject in need thereof.18 cl, 4 dwg, 4 ex
Combined administration of gdf traps and erythropoetin receptor activators for increasing content of erythrocytes // 2642302
FIELD: biotechnology.SUBSTANCE: method of treatment comprises of administration to the patient of an isolated polypeptide including the amino acid sequence of SEQ ID NO: 28.EFFECT: invention makes it possible to effectively increase the contents of erythrocytes in patients.17 cl, 22 dwg, 19 ex

Immunotherapeutic compositions on the basis of yeast-muc1 and methods of their use // 2642300
FIELD: biotechnology.SUBSTANCE: fusion protein is produced which contains the MUC1 antigen having an amino acid sequence that is at least 85% identical to the sequence of SEQ ID NO: 25 or at least 95% identical to the positions 92-566 of the sequence of SEQ ID NO: 25, and where MUC1 antigen contains 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of the following amino acids L184, Y232, L233, V240, V241, L242, Y483, V497, L335, F536 and Y551.EFFECT: invention allows to effectively treat Mucin-1-expressing carcinomas, and also to prevent their metastatic progression.14 cl, 3 dwg, 5 tbl, 10 ex

P53 peptidomimetic macrocycles // 2642299
FIELD: biotechnology.SUBSTANCE: stable cross-linked p53 peptidomimetic macrocycle, a method for its preparation and its use are proposed. The p53 peptidomimetic macrocycle has a structure represented in the formula, and interferes with binding of p53 to MDM2 and/or p53 to MDMX. The P53 peptidomimetic macrocycle can be used to prepare pharmaceutical compositions for treatment of cancer characterized by undesirably low or low p53 activity and/or for the treatment of cancer characterized by undesirably high levels of MDM2 or MDMX activity.EFFECT: proposed cross-linked p53 macrocycle has cell permeability that is at least twice as high as that of the corresponding macrocycle without cross-links.50 cl, 7 dwg, 9 tbl, 22 ex

Hpv chimeric particle // 2642287
FIELD: biotechnology.SUBSTANCE: chimeric virus-like particle (VLP) of human papilloma virus (HPV), and method for its production and extraction, methods for prevention or treatment of HPV infection or cervical cancer, and for induction of an immune response in the patient, including the administration of proposed HPV VLP, as well as the application of the proposed HPV VLP in these methods and in production of pharmaceuticals to implement these methods, are proposed. The proposed chimeric HPV VLPS has a diameter of about 30 nm and contains a chimeric polypeptide HPV 16 L1/L2, which consists of a polypeptide HPV 16 L1, in which the peptide HPV 16 L2 from the amino acid residue 414 is inserted. The peptide contains from 13 to 26 amino acids. The amino acids of the inserted HPV 16 L2 peptide replace the corresponding amino acids of the HPV 16 L1 polypeptide. A method is also provided for the production of said HPV VLP in a plant in which successful assembly of small chimeric HPV VLPs, having a diameter of 30 nm, takes place.EFFECT: proposed group of inventions can be used in medicine for the prevention or treatment of HPV infection or in antitumor therapy for cervical cancer.28 cl, 32 dwg, 11 tbl, 3 ex

Composition for hyperlipidemia treatment containing oxyntomodulin derivative // 2642267
FIELD: biotechnology.SUBSTANCE: oxyntomodulin derivative with SEQ ID NO: 24, 25 or 26 fused to the Fc region of the immunoglobulin via a non-peptidyl polymer that covalently binds the oxyntomodulin derivative and the immunoglobulin Fc region is obtained.EFFECT: invention allows to obtain a conjugate of a oxyntomodulin derivative with a high ability to activate the GLP-1 receptor and a glucagon receptor compared to natural oxyntomodulin and to effectively lower the levels of total cholesterol, low density cholesterol and triglycerides in blood that have been elevated due to a high fat diet and to raise high-density cholesterol levels and high-density cholesterol - low-density cholesterol ratios.13 cl, 10 dwg, 3 tbl, 6 ex

Polypeptide for blood sugar level reducing on basis of human glucagon-like peptide-1, recombinant producing strain e. coli and method of obtaining this polypeptide // 2642260
FIELD: biotechnology.SUBSTANCE: recombinant modified human glucagon-like peptide-1 (rmGLP-1), a method for its preparation, and strain E.coli RNCIM B-12555 are proposed. rmGLP-1 has the sequence of SEQ ID NO 1. rmGLP-1 is produced by culturing a recombinant strain E. coli RNCIM B-12555 to prepare the rmGLP-1 peptide precursor, then isolating the resulting precursor, its autocatalytic cleavage and purification of the target polypeptide. The mouse model shows that with subcutaneous or intramuscular administration, rmGLP-1 has indicators of sugar reduction activity and duration of action similar to that of the commercial preparation "Lysxemia" obtained using chemical synthesis and, for a minimum of 3 hours after administration, is able to effectively reduce the level of glucose in blood almost twice as compared with the control.EFFECT: abovementioned strain allows biosynthesis of the precursor rmGLP-1 at 40 percent of the total protein of the cells, which corresponds to the biosynthesis of rmGLP-1 at 13 percent of the total cell protein.3 cl, 3 dwg, 7 ex

ethod for introgression of pathogenic streptococcus genes in chromosomal dna of probiotic strain of enterococcus faecium l3 for expression in piles // 2640250
FIELD: biotechnology.SUBSTANCE: invention relates to a method of producing a live vaccine on the basis of biologically active strain Enterococcus faecium L3 due to the itrogression of the antigen of a clinically relevant pathogenic microorganism into the structure of the strain piles. This method involves producing a fusion gene of entF-bac, consisting of two separate gene fragments of probiotic E.faecium L3 and gene fragment bac and having a nucleotide sequence, shown in fig. 7a, its cloning and detection of bacterial clones expressing the desired protein in piles. The invention also relates to recombinant plasmid DNA pentF-bac. The real DNA pentF-bac is designed to create a live vaccine based on the biologically active strain of E. faecium L3. This pentF-bac DNA is a suicide plasmid pT7ERMB, at BamHI and KpnI sites of which the sequence of entF-bac fusion gene DNA is inserted. The present invention also relates to a vaccine preparation of E.faecium L3 Bac+. This vaccine preparation is prepared by electroporation of E. faecium L3 of plasmid pentF-bac DNA.EFFECT: invention allows for the production of a live vaccine based on the biologically active strain.3 cl, 9 dwg, 1 tbl, 5 ex

Bis-met-histones // 2640247
FIELD: biotechnology.SUBSTANCE: nucleic acid molecule encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked through a peptide bond to the mature eukaryotic histone H1. 3. A polypeptide is prepared by culturing a host cell transformed with an expression vector comprising the said nucleic acid molecule. The polypeptide is used as part of a pharmaceutical composition for treatment of cancer, bacterial, viral or fungal infections. Also, the polypeptide is used as part of a composition for diagnosing a patient with respect to the presence of a response to a pharmaceutical composition containing the said polypeptide, or with respect to curability thereof.EFFECT: invention allows to increase the efficiency of recombinant expression and facilitate the determination of the said polypeptide in the presence of endogenous histones while maintaining biological activity of the mature eukaryotic histone.16 cl, 3 dwg, 6 tbl, 7 ex
Bifunctional peptide // 2639573
FIELD: biotechnology.SUBSTANCE: invention relates to the field of biotechnology, specifically to the bifunctional peptide capable of activating collagen synthesis and inhibiting matrix metalloproteinase production, and can be used in medicine and cosmetology. Bifunctional peptide has a sequence of three peptide regions a, b, and c. The first region A is hexapeptide, repeated at least three times, capable of communicating with an elastin-binding receptor protein to stimulate collagen synthesis. The second region B is tetrapeptide capable acting as a competitive inhibitor of urokinase protease and cleaving by the said protease. The third region C is tripeptide that occupies at least one active site of matrix metalloproteinases to permit inhibition of these proteinases.EFFECT: invention allows to effectively stimulate collagen synthesis and inhibit the production of matrix metalloproteinases for treatment of chronic cicatricial diseases, sores, or ulcers for skin tissue recovery or regeneration and for skin anti-aging.18 cl, 7 ex, 8 dwg

Peptides suppressing respiratory viruse infections, their application and methods for obtaining // 2639559
FIELD: pharmacology.SUBSTANCE: inventions relate to a peptide synthesized chemically or genetically engineered, compositions comprising such a peptide, DNA coding a polypeptide, vector incorporating such a DNA, a host cell for expression of the peptide, a peptide screening Kit, capable of suppressing a respiratory virus infection and a method for screening of a peptide capable of suppressing a respiratory virus infection. The presented peptide contains 5 or more essential amino acids, 2 or more of these essential amino acids are located in the N-terminal or C-terminal region, and the N-terminal region contains a sequence of no more than 10 amino acids from the peptide N-terminal amino acid and the C-terminal region contains a sequence of no more than 10 amino acids from the peptide C-terminal amino acid, while the peptide consists of a sequence of amino acids, at least 90% identical to SEQ ID NO: 10.EFFECT: possibility of application of inventions to block infections of respiratory viruses such as influenza viruses or coronaviruses in the target cells for prevention and treatment of these infections.23 cl, 10 dwg, 3 tbl, 1 ex

Computer-optimized antigens with wide reactivity spectrum for influenza viruses of h5n1 and h1n1 // 2639551
FIELD: biotechnology.SUBSTANCE: recombinant influenza hemagglutinin (HA) polypeptide to elicit an immune response to the H5N1 influenza virus containing the amino acid sequence from residues 2-568 of SEQ ID NO: 1 encoding its nucleic acid containing the proposed polypeptide fusion protein and virus-like particle (VLP) to elicit a response to the H5N1 influenza virus, an expression vector containing the nucleic acid, and an isolated cell containing it, a composition and method for eliciting an immune response to the H5N1 influenza virus, and a method for immunizing a subject are proposed. The proposed group of inventions can be used in medicine for immunization against the H5N1 influenza virus.EFFECT: proposed protein, VLP, and compositions are capable of eliciting an immune response with a wide range of reactivity to the H5N1 influenza virus.19 cl, 8 dwg, 5 ex

ethod of cleaning protein included in self-immolative tape and its application // 2639527
FIELD: biotechnology.SUBSTANCE: invention relates to a self-immolative chimeric protein for cleaning a target protein, a nucleic acid which encodes it, and also to a vector and a host cell containing the above-mentioned nucleic acid. A method of cleaning a target protein, comprising cultivating the above-mentioned cell, is also disclosed. The invention also relates to a method of producing a therapeutic antibody-drug conjugate using the above-mentioned chimeric protein.EFFECT: invention allows effictive cleaning of the target protein.29 cl, 17 dwg, 7 ex

Fusion polypeptide containing wap domain and their application methods // 2639526
FIELD: biotechnology.SUBSTANCE: fusion proteins having at least one polypeptide of the human secretory inhibitor of leukocyte proteases (SLPI) operably linked to an immunoglobulin Fc fragment polypeptide having an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:10 are obtained.EFFECT: invention allows to obtain a fusion polypeptide capable of effectively inhibiting the activity of neutrophilic serine proteases and thereby alleviating the symptoms of diseases or disorders associated with overexpression or serine protease activity in a subject in need thereof.15 cl, 4 dwg, 4 ex

Peptidomimetic macrocycles and their application // 2639523
FIELD: biotechnology.SUBSTANCE: peptidomimetic macrocycle is proposed that binds to the Growth-Hormone-Releasing Hormone (GHRH) receptor and its use. The peptidomimetic macrocycle proposed has a structure as shown in the formula.EFFECT: peptidomimetic macrocycle has improved biological activity, stimulates the production and release of growth hormone and can be used to increase lean muscle mass in the patient, to reduce adipose tissue in the patient, to treat muscle atrophy, lipodystrophy, growth hormone, gastric paresis, or short-term syndrome guts in a patient.31 cl, 11 dwg, 5 tbl, 4 ex

Analogues of complement factor b and their application // 2639521
FIELD: biotechnology.SUBSTANCE: invention can be used in medicine to treat a disease mediated by activation of an alternative complement pathway. A polypeptide consisting of hfB3-292S (amino acids 1-764 or 26-764 in SEQ ID NO: 2), hfB3-292SN480 (amino acids 1-480 or 26-480 in SEQ ID NO: 2) or hfB3-292S-Fc (amino acids 1-990 or 26-990 in SEQ ID NO: 22) is obtained.EFFECT: invention allows to effectively inhibit the activity of the alternative complement pathway when using the resulting polypeptide, coding its nucleic acid or expression vector.12 cl, 14 dwg, 6 tbl, 19 ex

Immunity inducing agent // 2639518
FIELD: medicine.SUBSTANCE: invention refers to the immunity inducing agent containing the effective number of at least one polypeptide with inducing immune system activity, which induces cytotoxic t-cells capable to destroy tumour cells expressing polypeptide CAPRIN-1. Also, method is represented to obtain the selected antigen-presenting cell in vitro, which presents polypeptide fragment CAPRIN-1 for class I molecule RENAMO t-cells, as well as in vitro method for obtaining selected cytotoxic t-cells specific to protein CAPRIN-1. The invention also relates to a method of induction of immunity, including the introduction of individual effective amount of at least one polypeptide with inducing immune system activity, which induces cytotoxic t-cells capable to destroy tumour cells expressing polypeptide CAPRIN-1.EFFECT: effectively destroys tumour cells expressing the CAPRIN-1 polypeptide.13 cl, 5 dwg, 6 ex

Enhancer of sugar cane baculovirus (scbv) and its application in functional genomics of plants // 2639517
FIELD: biotechnology.SUBSTANCE: invention relates to a structure for enhancing transcription of a nucleotide sequence, which is of interest. A transgenic corn plant or Aspergillus nidulans, a seed, a cell, a tissue, a fruit, a root, a shoot, a flower, a cut, containing said structure, are also disclosed. Methods for the production of a transgenic plant using the above structure, a method for reducing the profile of fatty acids are disclosed.EFFECT: invention allows for the production of a transgenic corn plant or Aspergillus nidulans having an enhanced transcription of the nucleotide sequence of interest as compared to the wild type.32 cl, 10 dwg, 3 tbl, 11 ex

Chemerical antigenes for vaccine against hepatitis c virus // 2639504
FIELD: pharmacology.SUBSTANCE: proposed inventions refer to chimerical antigens, vaccine composition, containing such a chimerical antigen, and use of chimerical antigen to obtain vaccines against hepatitis C virus (HCV). Described chimerical anetigen consists of a) the first segment, consisting of area E2 (amino acid 408-540) of HCV poliprotein, b) of the second segment, consisting of area E1 (amino acid 190-222) of HCV poliprotein, and c) of the third segment, consisting of Core area (amino acid 1-50) of this protein, in that order.EFFECT: strong immune response of a broad spectrum against various antigens of the virus.14 cl, 25 dwg, 7 ex
Escherichia coli strain - producer of modular nanoconveyor for delivery of pharmaceutical agents to nuclei of target cells // 2639501
FIELD: biotechnology.SUBSTANCE: invention relates to E. coli RosettaTM strain (pRARE2, pR752), RNCIM B-11308. This strain is a producer of a modular nanoconveyor to increase the specificity and effectiveness of antitumor agents of 6His-HMP-NLS-DTox-(Gly-Ser)5-EGF. The present invention makes it possible to obtain a modular 6His-HMP-NLS-DTox-(Gly-Ser)5-EGF nanoconveyor.EFFECT: increase in the specificity and effectiveness of antitumor agents.2 dwg, 2 ex

Liposomes containing oligopeptide fragments of myelin basic protein, pharmaceutical composition and method for multiple sclerosis treatment // 2639497
FIELD: biotechnology.SUBSTANCE: invention relates to the production of liposomes with a peptide of the myelin basic protein (MBP), and can be used in medicine for multiple sclerosis treatment. A composition is prepared containing the MBP peptide with SEQ ID NO: 11 or SEQ ID NO: 12 bound to the first vector, wherein the vector comprises a liposome having a surface exposed to the target portion that contains a mannose residue or a mannose derivative.EFFECT: invention provides greater therapeutic benefit than copaxone, therapeutically approved for the treatment of relapsing-remitting multiple sclerosis.18 cl, 14 dwg, 14 tbl, 14 ex

ethods and compositions for huntington disease treatment // 2639277
FIELD: biotechnology.SUBSTANCE: invention refers to a "zinc fingers" protein of non-natural origin that binds to the Htt gene, which can be used in medicine. The specified "zinc fingers" protein, as well as fusion protein that includes the specified protein functionally associated with a nuclease domain, a polynucleotide, encoding the specified protein and the specified fusion protein, a host cell for obtaining of the specified protein and the specified fusion protein, a pharmaceutical composition for Htt gene expression suppression in the cell are obtained. The invention also provides a method for Htt gene expression suppression, a method for Huntington's disease treatment.EFFECT: invention effectively suppresses the Htt gene expression, which allows successful treatment of Huntington's disease.24 cl, 15 dwg, 7 tbl, 20 ex

Improved method for physiologically active polypeptide conjugate production // 2639256
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, specifically to the preparation of conjugates of a physiologically active polypeptide with a non-peptidyl polymer and a constant region of an immunoglobulin, and can be used in medicine to create long-acting compositions of physiologically active polypeptides that improve adherence to medication.EFFECT: method differs by varying the concentrations of the reducing agent from 1 mM to less than 20 mM at the first stage and from 1 to 100 mM at the second stage of reductive amination, thereby overcoming the traditional problems of low yield of a modified polypeptide with a prolonged action profile.25 cl, 4 tbl, 7 ex

Application of s-layer protein domain from lactobacillus brevis as component of system for film proteins exposure on lactic acid bacteria cells surface // 2639246
FIELD: biotechnology.SUBSTANCE: polypeptide is a N-terminal domain for attachment to the cell wall of the S-layer protein lvis_2083 of the Lactobacillus brevis ATCC 367 bacterial strain.EFFECT: expanded arsenal of proteins suitable for use as a component of the system for fusion proteins exposure on the lactic acid bacteria cells surface.3 dwg, 7 ex
Histones and biodegradable lipides as means for nucleic acids delivery to eukaryotic cells // 2637371
FIELD: biotechnology.SUBSTANCE: genetic material is delivered to the eukaryotic cells by binding the plasmid DNA in a complex with the recombinant H2A or H2A-TAT histone in the presence of a biodegradable lipide represented by choline fatty acid ester.EFFECT: compared with non-viral analogs, the invention allows to deliver the genetic material to eukaryotic cells of interest more efficiently.12 cl, 6 dwg, 10 ex

Photosensitive chimeric protein gpcr // 2637367
FIELD: biotechnology.SUBSTANCE: invention relates to production of a photosensitive chimeric protein capable of incorporating a light signal into the signalling cascade of metabotropic glutamate receptor 6 (mGluR6), which is a natural component of the ON-bipolar cell membrane in the inner layer of the retina, which can be used in medicine. A GPCR chimeric protein is obtained comprising domains of at least two members of a protein receptor superfamily conjugated with G proteins (GPCR), a nucleic acid encoding the said protein, an expression vector comprising the said nucleic acid, as well as a transgenic cell line containing genetic information, encoding a chimeric GPCR protein.EFFECT: invention allows effective drug therapy and production of an effective drug for vision improvement, in particular, for treatment of vision loss due to degeneration of retinal photoreceptors.32 cl, 6 dwg, 1 tbl, 1 ex

New npr-b agonists // 2636738
FIELD: pharmacology.SUBSTANCE: invention relates to new peptides having the activity of NPR-B agonists that can be used to treat and prevent disorders mediated by natriuretic peptides, for example, such as glaucoma, eye hypertension and optical neuropathies.EFFECT: increased efficiency of treatment.21 cl, 3 dwg, 5 tbl, 5 ex

Improved n-terminal capping modules for constructed ankyrin repeat proteins // 2636552
FIELD: biotechnology.SUBSTANCE: invention relates to N-terminal capping modules for proteins. The resulting N-terminal capping modules for constructed ankyrin repeat (DARPin) proteins provide greater thermal stability of DARPin compared to the unmodified protein.EFFECT: increased compound stability.21 cl, 3 ex, 1 tbl, 4 dwg

New peptide with 4 linked ctl-epithopes // 2636549
FIELD: biotechnology.SUBSTANCE: invention can be used in medicine to induce anti-tumour immunity against expression of Lck, WHSC2, SART2, SART3, UBE2V, EGFR, PTHrP or MRP3 cancer. A peptide is obtained from 4 CTL epitopes of cancer antigens linked through amino acid linkers. The resulting peptide is used to stimulate peripheral blood lymphocytes to obtain a combination of CTL specific for the cancer antigen.EFFECT: invention allows to obtain a peptide vaccine for cancer treatment in a wide range of patients without the necessity of HLA-typing and regardless of the HLA types in patients.11 cl, 17 dwg, 4 tbl, 5 ex

Split product vaccine against mycoplasma spp // 2636459
FIELD: biotechnology.SUBSTANCE: invention relates to the production of split product vaccines against Mycoplasma spp., and can be used in medicine to prevent the Mycoplasma spp. infection. Vaccine compositions based on the Mhp145 protein with SEQ ID NO: 11 in combination with a pharmaceutically acceptable adjuvant, XylF protein with SEQ ID NO: 09 and/or a pharmaceutically acceptable additive are proposed.EFFECT: achievement of strong immune effects against Mycoplasma spp.6 cl, 4 dwg, 9 tbl, 3 ex

Glycosylated polypeptide and its pharmaceutical composition // 2636456
FIELD: pharmacology.SUBSTANCE: glycosylated polypeptide with a homogeneous structure of the sugar chain and having interferon-β activity is obtained synthetically.EFFECT: sugar chain structure homogeneity and presence of sialic acid on the non-reducing end of the sugar chain increases the half-life of the glycosylated form of interferon in blood and improves its pharmacokinetic properties.12 cl, 50 dwg, 2 tbl, 12 ex

Ospa chimeric genes, proteins, and methods for their use // 2636455
FIELD: biotechnology.SUBSTANCE: invention relates to development of outer surface protein A (OspA) chimeric molecules, and can be used in medicine. The designed chimeric polypeptide with SEQ ID NO: 173, as well as compositions and combined vaccines that contain it, are able to elicit a specific immune response against bacteria of Borrelia genus.EFFECT: invention can effectively treat and prevent Borrelia infections or Lyme disease.36 cl, 24 dwg, 9 tbl, 22 ex

olecule containing spr0096 and spr2021 // 2636350
FIELD: biotechnology.SUBSTANCE: conjugate containing a bacterial capsular saccharide, for example, a capsular saccharide from N. meningitidis serogroup A, C, W135 or Y, covalently bound to a carrier molecule, wherein the carrier molecule contains a single polypeptide chain consisting of one antigen spr0096 and one antigen spr2021.EFFECT: expansion of the arsenal of technical means in terms of text visualization, enhanced immune response to saccharide compared to the CRM197 carrier protein.15 cl, 18 dwg, 5 tbl

ethod for obtaining of recombinant exoprotein of a pseudomonas aeruginosa // 2636346
FIELD: biotechnology.SUBSTANCE: method includes obtaining of expression plasmid vector pET-rEPA (SEQ NO: 3), containing a promotor sequence of T7 bacteriophage DNA and DNA sequences encoding the N-end region of protein product of translation enhancer (MASMT amino-acid sequence), six histidine residues, site of SUMO protease cleavage and a sequence (SEQ NO: 1) optimized for broadcasting in E. coli encoding recombinant rEPA protein (SEQ NO: 2). Recombinant chimeric precursor protein in the heterological expression system in electro-competent cells of E. coli BL21 (DE3), transformed by the plasmid vector pET-rEPA to obtain a E. coli BL-rEPA strain at 37°C to ensure the maximum amount of accumulation of precursor protein in the soluble fraction. Lysis of the bacterial mass is carried out in the presence of 4% Triton X-100 to preserve the precursor protein in a soluble form. The precursor protein is isolated by metal chelate chromatography on Talon sorbent charged with Co2+ ions, followed by hexahistidine and SUMO peptide cleavage with SUMO protease from the polypeptide. The cleaved recombinant protein rEPA is subject to finish purification by anion-exchange chromatography on DEAE-Sepharose sorbent and gel-filtration chromatography on a Superdex 200-filled column, with translation to the target buffer with pH of 7.5, obtaining the recombinant rEPA protein.EFFECT: production of protein in high yield.4 dwg, 4 ex
eans for stimulation of differentiation of pancreatic progenitors of beta-cells into insulin producing and secreting beta-cell in case of insulin-dependent diabetes mellitus // 2636044
FIELD: medicine.SUBSTANCE: this invention relates to a means for stimulation of the differentiation of pancreatic beta-cell precursors into insulin producing and secreting beta-cells in insulin-dependent diabetes mellitus. This agent is a pegylated form of glucagon-like peptide 1 of GLP-1 (7-37).EFFECT: ability of the means to stimulate the differentiation of pancreatic beta-cell precursors into insulin producing and secreting beta-cells.1 dwg, 9 tbl, 7 ex

Amino-acid sequences for control of pathogen // 2636001
FIELD: biotechnology.SUBSTANCE: inventions relate to antimicrobial peptides selected and purified from extracts of tilapia gill (Oreochromis niloticus), and also methods and compositions in which they can be used. The presented peptides can be obtained by chemical synthesis or expression in a heterologous system, such as bacteria and yeast, using conventional molecular-biological techniques. Peptides have antimicrobial activity against various organisms, including gram-positive bacteria, gram-negative bacteria, fungi and viruses.EFFECT: inventors can effectively enhance the immune response induced by various antigens, and monitor the progression of diseases caused by pathogens.16 cl, 9 dwg, 1 tbl, 10 ex

Recombinant plasmid pet40cmap/ mpf dna, encoding bifunctional hybrid cmap/ompf polypeptide with properties of highly-active alkaline phosphatase cmap and pore-forming membrane ompf protein, and recombinant strain of e. coli rosetta (de3)/pet40cmap/ompf - producer of bifunctional hybrid cmap/ompf polypeptide // 2634871
FIELD: biotechnology.SUBSTANCE: said plasmid is characterized by presence of the following fragments: a NcoI/SalI fragment of pET-40b(+) plasmid (Novagen) and a 2577 bp DNA fragment containing a chimeric gene encoding the full-length alkaline phosphatase CmAP and the full-length Yersinia pseudotuberculosis OmpF porin, linked together by a sequence encoding a flexible linker (G4S)3 (SEQ ID NO: 1). A recombinant strain of E. coli Rosetta (DE3)/pET40CmAP/OmpF, which is a producer of a bifunctional hybrid CmAP/OmpF polypeptide, and which is obtained by modification of the E. coli Rosetta (DE3) strain with this pET40CmAP/OmpF plasmid, is proposed.EFFECT: high yield of hybrid protein with the properties of recombinant highly-active alkaline phosphatase and pore-forming protein.2 cl, 2 dwg, 3 ex

Humanized il-6 and il-6 receptor // 2634417
FIELD: biotechnology.SUBSTANCE: invention relates to genetically modified mouse family animals, namely, to mice and rats that express human IL-6 and may further express humanized IL-6Rα. This animal carries the replacement of its gene encoding IL-6 at its endogenous locus IL-6 with the human gene encoding human IL-6 and further replacement of the sequence encoding animal extracellular domain IL-6Rα at its endogenous locus IL-6Rα, with the sequence encoding the humen extracellular domain IL-6Rα to produce a humanized IL-6Rα gene. At that, the human gene encoding human IL-6 and humanized IL-6Rα gene are controlled by the endogenous regulatory elements of the animal at its endogenous locus IL-6 and IL-6Rα respectively. This humanized IL-6Rα gene contains endogenous transmembrane and cytoplasmic sequences of IL-6Rα of the said animal. The invention also discloses a method for obtaining of these animals and isolated embryonic stem cells for obtaining of such animals.EFFECT: invention allows to obtain transgenic mice and rats without any pathology.18 cl, 15 dwg, 3 tbl, 3 ex
ethod for production of active pharmaceutical substance of recombinant bismetionilystone h1.3 // 2634408
FIELD: biotechnology.SUBSTANCE: method involves cultivation of the E. coli strain B121 (DE3)/pEGT1/H1.3S producing the target protein, biomass disintegration, target protein extraction with perchloric acid, and subsequent purification of the target protein. This method is characterized by protein purification involving purification by cation exchange chromatography using washing of a sorbent coated with protein with a solution of 4 M urea and purification by HPLC. This method also comprises concentration of the purified bismethionylhistone by ultrafiltration and lyophilization to obtain a purified bismethionylhistone powder with a purity of 98.5%.EFFECT: preparation of bismethionylgystone of compendial grade.2 ex

Food proteins fragments and methods for their application // 2634407
FIELD: biotechnology.SUBSTANCE: dedicated food protein, a nucleic acid, coding such a protein expression vector containing the nucleic acid sequence, a cell, a host and a method to obtain this protein are provided. The represented food protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2580, 2582, 2587, 2595, 2596, 2598, 2599 and 2603. Protein is soluble in water at pH 7 to at least 12.5 g/l, as well as during its semi-digestion in artificial gastric juice is less than 10 minutes.EFFECT: improved method.5 cl, 2 dwg, 14 tbl, 12 ex
Fused protein, inhibiting angiogenesis or growth of vessels, and its application // 2634406
FIELD: biotechnology.SUBSTANCE: fused protein consisting of the KH02, KH03 or KH04 fragments of the receptor of human vascular endothelial growth factor (VEGF) of the human and the human immunoglobulin Fc-fragment, bound together, is obtained.EFFECT: invention makes it possible to obtain a biologically active fused protein with high thermal stability, a significantly reduced rate of formation of protein aggregates during the fermentation process, and a substantial increase of the purity and yield of the protein.15 cl, 4 dwg, 11 tbl, 7 ex

ethod for obtaining of recombinant peptidoglycan-associated lipoprotein (pal) legionella pneumophila // 2634385
FIELD: biotechnology.SUBSTANCE: method for obtaining of recombinant peptidoglycan-associated lipoprotein (PAL) Legionella pneumophila is proposed. A pET22b(+)-PAL plasmid with length of 6184 is constructed, bearing an expression construct for production of a chimeric polypeptide containing a sequence encoding a PAL protein fused at the 5'-end with a synthetic sequence encoding six histidins and a SUMO peptide. E. coli BL21 (DE3) cells are transformed with the expression plasmid DNA pET22b(+)-PAL. The resulting BL21(DE3)-PAL strain is cultured at 37°C with production of PAL protein for 3 hours. The HIS-SUMO-PAL protein is purified from the soluble fraction of bacterial lysate by metal-chelate chromatography. The HIS-SUMO peptide is cleaved by treatment with SUMO protease to restore the native structure of the PAL protein. Using ion-exchange and gel filtration chromatography, a homogeneous preparation of the PAL protein is obtained.EFFECT: invention provides a PAL protein having 98 percent purity based on electrophoresis and densitometry data, yielding at least 300 mg per litre of bacterial culture without fermentation, which can be used in development of diagnostic preparations for legionellosis determination.5 dwg, 3 ex

Improved nano-bodies against human serum albumin // 2634381
FIELD: biotechnology.SUBSTANCE: nano-bodies of the invention are used to prepare bispecific and trispecific polypeptides by binding them to one or two nano-bodies against antigens other than human serum albumin.EFFECT: invention allows preparation of nano-bodies and polypeptides containing them, having improved affinity for human serum albumin.29 cl, 62 dwg, 47 tbl, 65 ex

odified biotin-binding protein, fusion proteins based thereon and their application // 2632651
FIELD: biotechnology.SUBSTANCE: fusion biotin-binding protein is obtained which comprises a soluble biotin-binding protein and an antigenic protein or peptide, the fusion protein does not include amino acids 1-44 of the wild-type Rizavidin protein.EFFECT: invention allows to express fusion biotin-binding proteins in soluble form and at a high yield, to increase the efficiency of formation of complexes of biotin-binding proteins and protein antigens.18 cl, 14 dwg, 5 tbl, 7 ex

odulation of structured proteins specificity // 2631931
FIELD: biotechnology.SUBSTANCE: ligands to human kallikrein, libraries of the said ligands and library sets of the said ligands are obtained by screening libraries of mutant peptides, characterized by the resulting ligand comprising the WPAR amino acid sequence.EFFECT: invention allows to obtain ligands for human kallikrein with increased specificity.15 cl, 16 dwg, 22 tbl, 6 ex

Coagulation factor viii with reduced immunogenicity // 2631801
FIELD: biotechnology.SUBSTANCE: method comprises: (a) identification of at least one epitope of NKT cells, wherein the motif of the said NKT cell epitope is [FWTHY]-X2X3-[ILMV]-X5X6-[FWTHY], wherein at least one NKT cell epitope is in SEQ ID NO: 1 and (b) modification of the said epitope(s) by replacing at least one hydrophobic amino acid residue at position P1 and P7 with one amino acid other than F, W, T, H, Y.EFFECT: invention allows to obtain an active molecule of factor VIII, which has a reduced ability to activate NKT cells due to reduced binding to the CD1d molecule.6 cl, 6 dwg, 1 tbl, 7 ex

Identification and application of mutantial krp in plants // 2631790
FIELD: biotechnology.SUBSTANCE: invention relates to an entire plant having increased seed weight, seed size and number of seeds, and increased yield by introducing certain mutations into said sequences of KRP protein gene, which is related to kinase inhibitor protein (KIP). Also, a whole wheat plant, having increased seed weight, seed size and the number of seeds, and an increased yield, is also disclosed by introducing certain mutations into said sequences of KRP protein gene, which is related to kinase inhibitor protein (KIP). A method for increasing seed weight, seed size, seed quantity, and crop yield is disclosed by introducing certain mutations into said sequences of KRP protein gene, which is related to kinase inhibitor protein (KIP).EFFECT: invention makes it possible to obtain plants with increased seed weight, seed size and the number of seeds, and to get an increased yield.10 cl, 15 dwg, 42 tbl, 10 ex

ethod for trib-2mut recombinant elastromerial domain, production, gene-engineering pgdtrib2mut construction, determining trib-2mut biosynthesis in e.coli cells, e.coli m15/pgdtrib2mut producing strain and method for polymer material obtaining based on this protein // 2631004
FIELD: biotechnology.SUBSTANCE: based on the minimal recombinant elastomeric motif (tribolin-1, Trib-1mut) insect resilinTribolium castaneum (tribolin-2, TRib-2mut), a protein structure is obtained recombinantly, which is used in aggregation methods to form the basis of a biomatrix network.EFFECT: invention allows to obtain polymeric frame biomaterial for tissue engineering.5 cl, 2 dwg, 2 tbl, 4 ex

Fusion proteins for application as immunogenic amplifying agents to induce antigen-specific t-cell response // 2631002
FIELD: biotechnology.SUBSTANCE: invention relates to fusion proteins for application as an immunogenic enhancing agent to enhance antigen-specific T-cell responses, and can be used in medicine. A fusion protein is produced recombinantly, which comprises: (a) a binding domain with an antigen-presenting cell (APC) or a binding domain with the CD91 receptor; (b) a protein transduction domain; (c) a pathogenic antigen. The binding domain with the antigen-presenting cell (APC) or the binding domain with the CD91 receptor is located at the N-terminus of the fusion protein, and the pathogenic antigen is located at the C-terminus of the protein transduction domain.EFFECT: invention allows to obtain an enhanced antigen-specific T-cell response against a viral pathogen and cancer cell.16 cl, 15 dwg, 2 tbl, 6 ex